CLINICAL_TRIALS
trial_result
· 2009-06-17
Clinical Trial Update: A Dose-Ranging Study of ATI 7505 in Patients With Postprandial Distress Syndrome [Phase 2]
Summary
A Phase 2 dose-ranging study of ATI 7505 in patients with postprandial distress syndrome was terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Procter and Gamble | Conditions: Post Prandial Distress Syndrome | Phase 2 | Status: TERMINATED